glp-1 for dogs Weight loss drugs cats? Company launches clinical trial of implants in cats Glucagonlike Peptide-1 Receptor Imaging in

ENaC in salt-sensitive hypertension: kidney and beyond

Pathogenic variants in CDKN2A may account for 35% to 40% of all familial melanomas

The Benefits of this program extend beyond just weight loss to improved metabolic health, energy levels, and overall well-being

While headline pharmaceutical research and development (R&D) returns have improved for the third consecutive year, reaching a 7.0 percent internal rate of return (IRR) in 2025, this recovery is largely driven by a few mega-blockbuster programs, notably glucagon-like peptide receptor agonists (GLP-1s) and GLP-1 combinations with gastric inhibitory polypeptide-based drugs (GIPs) in obesity, masking broader R&D pressures

In that setting, patients received high-dose NAD+ daily for about 4-10 days to alleviate acute withdrawal symptoms, followed by tapering to less frequent booster injections over the ensuing weeks